Daunorubicin/cytarabine

Last updated

Daunorubicin/cytarabine
Cytarabin.svg
Cytarabine
Daunorubicin2DACS.svg
Daunorubicin
Combination of
Daunorubicin Anthracycline
Cytarabine Antimetabolite
Clinical data
Trade names Vyxeos
Other namesCPX-351
AHFS/Drugs.com Monograph
License data
Pregnancy
category
Routes of
administration 		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Daunorubicin/cytarabine, sold under the brand name Vyxeos, is a fixed-dose combination medication used for the treatment of acute myeloid leukemia. [4] [6] It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor. [4]

Medical uses

Daunorubicin/cytarabine is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in people aged one year of age and older. [4] [7] [8] [9] [10]

References

  1. 1 2 "Vyxeos APMDS". Therapeutic Goods Administration (TGA). 15 June 2022. Archived from the original on 18 June 2022. Retrieved 18 June 2022.
  2. ↑ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada . 3 August 2022. Retrieved 25 March 2024.
  3. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  4. 1 2 3 4 "Vyxeos (- daunorubicin and cytarabine liposome injection, powder, lyophilized, for suspension". DailyMed. 13 April 2021. Archived from the original on 29 March 2021. Retrieved 18 June 2022.
  5. ↑ "Vyxeos liposomal EPAR". European Medicines Agency (EMA). 23 August 2018. Retrieved 25 May 2024.
  6. ↑ Molica M, Perrone S, Mazzone C, Cesini L, Canichella M, de Fabritiis P (June 2022). "CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML". Cancers. 14 (12): 2843. doi: 10.3390/cancers14122843 . PMC   9221356 . PMID   35740508.
  7. ↑ "Vyxeos (cytarabine/daunorubicin liposomal) dosing, indications, interactions, adverse effects, and more". Medscape. Archived from the original on 15 August 2017. Retrieved 19 March 2019.
  8. ↑ "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Archived from the original on 11 April 2019. Retrieved 30 December 2018.
  9. ↑ Chen EC, Fathi AT, Brunner AM (2018). "Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML". OncoTargets and Therapy. 11: 3425–3434. doi: 10.2147/OTT.S141212 . PMC   6003284 . PMID   29928134.
  10. ↑ Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rorà A, et al. (October 2020). "CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia". Minerva Medica. 111 (5): 455–466. doi:10.23736/S0026-4806.20.07017-2. PMID   32955826. S2CID   221842680.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.